Tazemetostat Hydrobromide

FDA label information for this drug is available at DailyMed.

Use in Cancer

Tazemetostat hydrobromide is approved to treat:

• Epithelioid sarcoma that is locally advanced or has metastasized (spread to other parts of the body). It is used in adults and in children aged 16 years and older whose disease cannot be removed by surgery.¹
• Follicular lymphoma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults:
  • Whose tumors have a certain mutation in the EZH2 gene and who have received at least two systemic therapies.¹
  • Who are not able to receive other therapies.¹

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that tazemetostat hydrobromide provides a clinical benefit in these patients.

Tazemetostat hydrobromide is also being studied in the treatment of other types of cancer.

More About Tazemetostat Hydrobromide

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Tazemetostat Hydrobromide - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Tazemetostat Hydrobromide - Check for trials from NCI's list of cancer clinical trials now accepting patients.